Indian J Pharm Close
 

Table 2: Incidence of immune checkpoint blocker-related immune-mediated adverse events by organ system and severity[11],[17],[21],[22],[25],[26],[27],[28],[57],[63],[64],[65],[66],[67]*

Table 2: Incidence of immune checkpoint blocker-related immune-mediated adverse events by organ system and severity<sup>[11],[17],[21],[22],[25],[26],[27],[28],[57],[63],[64],[65],[66],[67]*</sup>